Baidu
map

IL-4/IL-13单抗DUPIXENT获得INESSS的积极推荐,用于治疗中度至重度特应性皮炎

2020-07-15 MedSci原创 MedSci原创

“患有中度至重度特应性皮炎对处于成长期的青少年来说,身心的损伤都是毁灭性的。INESSS的推荐将使这些青少年患者有机会获得DUPIXENT的治疗。 ”

赛诺菲宣布魁北克卫生保健机构(INESSS)推荐将DUPIXENT(dupilumab)用于治疗12-17岁、在当前治疗条件下疾病无法控制的、中度至重度的特应性皮炎患者。

赛诺菲加拿大的总经理表示:“患有中度至重度特应性皮炎对处于成长期的青少年的来说,身心的损伤都是毁灭性的。INESSS的推荐将使这些青少年患者有机会获得DUPIXENT的治疗。 ”

关于DUPIXENT

DUPIXENT是一个全人源单克隆抗体,靶向抑制白细胞介素-4(IL-4)和白介素-13(IL-13)的信号传导。

See the source image

图片来源:https://www.sec.gov/Archives/edgar/data/872589/000110465917001558/a17-1670_1ex99d1.htm

DUPIXENT在2017年11月30日,首次获得加拿大卫生部批准用于治疗中度至重度特应性皮炎成人患者。2019年9月,加拿大卫生部将批准范围扩大到12岁以上的青少年。

关于特应性皮炎

特应性皮炎是湿疹最常见的形式,是一种慢性炎症性疾病,以中度至重度形式出现。其皮疹可能会覆盖身体的大部分部位,并引起剧烈持续的瘙痒、皮肤病变和皮肤干燥、开裂、发红或变暗和渗出。控制不当的特应性皮炎会造成不良的生理、情感和社会心理影响,引起睡眠障碍、焦虑和抑郁以及孤立感。

原始出处:

https://www.firstwordpharma.com/node/1740302?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2057836, encodeId=525e205e836a2, content=<a href='/topic/show?id=9497963485' target=_blank style='color:#2F92EE;'>#IL-13单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9634, encryptionId=9497963485, topicName=IL-13单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Thu Jan 21 00:07:04 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784843, encodeId=26211e8484313, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6331, encryptionId=00e4633166, topicName=Dupixen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Mon Jun 14 12:07:04 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796926, encodeId=93431e969261b, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Wed Jun 02 22:07:04 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372746, encodeId=277713e274656, content=<a href='/topic/show?id=91a7633258' target=_blank style='color:#2F92EE;'>#Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6332, encryptionId=91a7633258, topicName=Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477307, encodeId=d41314e730734, content=<a href='/topic/show?id=c5d796e31e' target=_blank style='color:#2F92EE;'>#IL-4/IL-13单抗Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9673, encryptionId=c5d796e31e, topicName=IL-4/IL-13单抗Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83677370380, createdName=ms5822920152752585, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508289, encodeId=14d61508289b5, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515419, encodeId=ffa515154196e, content=<a href='/topic/show?id=b5e022149cc' target=_blank style='color:#2F92EE;'>#中度至重度特应性皮炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22149, encryptionId=b5e022149cc, topicName=中度至重度特应性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ad510789639, createdName=ms6980045490879608, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802921, encodeId=fac780292189, content=<a href='/topic/show?id=2ad83e51258' target=_blank style='color:#2F92EE;'>#双特异性抗体#</a>真是大火👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37512, encryptionId=2ad83e51258, topicName=双特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jul 15 22:49:45 CST 2020, time=2020-07-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2057836, encodeId=525e205e836a2, content=<a href='/topic/show?id=9497963485' target=_blank style='color:#2F92EE;'>#IL-13单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9634, encryptionId=9497963485, topicName=IL-13单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Thu Jan 21 00:07:04 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784843, encodeId=26211e8484313, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6331, encryptionId=00e4633166, topicName=Dupixen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Mon Jun 14 12:07:04 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796926, encodeId=93431e969261b, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Wed Jun 02 22:07:04 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372746, encodeId=277713e274656, content=<a href='/topic/show?id=91a7633258' target=_blank style='color:#2F92EE;'>#Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6332, encryptionId=91a7633258, topicName=Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477307, encodeId=d41314e730734, content=<a href='/topic/show?id=c5d796e31e' target=_blank style='color:#2F92EE;'>#IL-4/IL-13单抗Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9673, encryptionId=c5d796e31e, topicName=IL-4/IL-13单抗Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83677370380, createdName=ms5822920152752585, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508289, encodeId=14d61508289b5, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515419, encodeId=ffa515154196e, content=<a href='/topic/show?id=b5e022149cc' target=_blank style='color:#2F92EE;'>#中度至重度特应性皮炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22149, encryptionId=b5e022149cc, topicName=中度至重度特应性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ad510789639, createdName=ms6980045490879608, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802921, encodeId=fac780292189, content=<a href='/topic/show?id=2ad83e51258' target=_blank style='color:#2F92EE;'>#双特异性抗体#</a>真是大火👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37512, encryptionId=2ad83e51258, topicName=双特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jul 15 22:49:45 CST 2020, time=2020-07-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2057836, encodeId=525e205e836a2, content=<a href='/topic/show?id=9497963485' target=_blank style='color:#2F92EE;'>#IL-13单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9634, encryptionId=9497963485, topicName=IL-13单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Thu Jan 21 00:07:04 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784843, encodeId=26211e8484313, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6331, encryptionId=00e4633166, topicName=Dupixen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Mon Jun 14 12:07:04 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796926, encodeId=93431e969261b, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Wed Jun 02 22:07:04 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372746, encodeId=277713e274656, content=<a href='/topic/show?id=91a7633258' target=_blank style='color:#2F92EE;'>#Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6332, encryptionId=91a7633258, topicName=Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477307, encodeId=d41314e730734, content=<a href='/topic/show?id=c5d796e31e' target=_blank style='color:#2F92EE;'>#IL-4/IL-13单抗Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9673, encryptionId=c5d796e31e, topicName=IL-4/IL-13单抗Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83677370380, createdName=ms5822920152752585, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508289, encodeId=14d61508289b5, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515419, encodeId=ffa515154196e, content=<a href='/topic/show?id=b5e022149cc' target=_blank style='color:#2F92EE;'>#中度至重度特应性皮炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22149, encryptionId=b5e022149cc, topicName=中度至重度特应性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ad510789639, createdName=ms6980045490879608, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802921, encodeId=fac780292189, content=<a href='/topic/show?id=2ad83e51258' target=_blank style='color:#2F92EE;'>#双特异性抗体#</a>真是大火👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37512, encryptionId=2ad83e51258, topicName=双特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jul 15 22:49:45 CST 2020, time=2020-07-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2057836, encodeId=525e205e836a2, content=<a href='/topic/show?id=9497963485' target=_blank style='color:#2F92EE;'>#IL-13单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9634, encryptionId=9497963485, topicName=IL-13单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Thu Jan 21 00:07:04 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784843, encodeId=26211e8484313, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6331, encryptionId=00e4633166, topicName=Dupixen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Mon Jun 14 12:07:04 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796926, encodeId=93431e969261b, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Wed Jun 02 22:07:04 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372746, encodeId=277713e274656, content=<a href='/topic/show?id=91a7633258' target=_blank style='color:#2F92EE;'>#Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6332, encryptionId=91a7633258, topicName=Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477307, encodeId=d41314e730734, content=<a href='/topic/show?id=c5d796e31e' target=_blank style='color:#2F92EE;'>#IL-4/IL-13单抗Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9673, encryptionId=c5d796e31e, topicName=IL-4/IL-13单抗Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83677370380, createdName=ms5822920152752585, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508289, encodeId=14d61508289b5, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515419, encodeId=ffa515154196e, content=<a href='/topic/show?id=b5e022149cc' target=_blank style='color:#2F92EE;'>#中度至重度特应性皮炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22149, encryptionId=b5e022149cc, topicName=中度至重度特应性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ad510789639, createdName=ms6980045490879608, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802921, encodeId=fac780292189, content=<a href='/topic/show?id=2ad83e51258' target=_blank style='color:#2F92EE;'>#双特异性抗体#</a>真是大火👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37512, encryptionId=2ad83e51258, topicName=双特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jul 15 22:49:45 CST 2020, time=2020-07-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2057836, encodeId=525e205e836a2, content=<a href='/topic/show?id=9497963485' target=_blank style='color:#2F92EE;'>#IL-13单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9634, encryptionId=9497963485, topicName=IL-13单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Thu Jan 21 00:07:04 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784843, encodeId=26211e8484313, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6331, encryptionId=00e4633166, topicName=Dupixen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Mon Jun 14 12:07:04 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796926, encodeId=93431e969261b, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Wed Jun 02 22:07:04 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372746, encodeId=277713e274656, content=<a href='/topic/show?id=91a7633258' target=_blank style='color:#2F92EE;'>#Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6332, encryptionId=91a7633258, topicName=Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477307, encodeId=d41314e730734, content=<a href='/topic/show?id=c5d796e31e' target=_blank style='color:#2F92EE;'>#IL-4/IL-13单抗Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9673, encryptionId=c5d796e31e, topicName=IL-4/IL-13单抗Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83677370380, createdName=ms5822920152752585, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508289, encodeId=14d61508289b5, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515419, encodeId=ffa515154196e, content=<a href='/topic/show?id=b5e022149cc' target=_blank style='color:#2F92EE;'>#中度至重度特应性皮炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22149, encryptionId=b5e022149cc, topicName=中度至重度特应性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ad510789639, createdName=ms6980045490879608, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802921, encodeId=fac780292189, content=<a href='/topic/show?id=2ad83e51258' target=_blank style='color:#2F92EE;'>#双特异性抗体#</a>真是大火👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37512, encryptionId=2ad83e51258, topicName=双特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jul 15 22:49:45 CST 2020, time=2020-07-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2057836, encodeId=525e205e836a2, content=<a href='/topic/show?id=9497963485' target=_blank style='color:#2F92EE;'>#IL-13单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9634, encryptionId=9497963485, topicName=IL-13单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Thu Jan 21 00:07:04 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784843, encodeId=26211e8484313, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6331, encryptionId=00e4633166, topicName=Dupixen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Mon Jun 14 12:07:04 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796926, encodeId=93431e969261b, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Wed Jun 02 22:07:04 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372746, encodeId=277713e274656, content=<a href='/topic/show?id=91a7633258' target=_blank style='color:#2F92EE;'>#Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6332, encryptionId=91a7633258, topicName=Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477307, encodeId=d41314e730734, content=<a href='/topic/show?id=c5d796e31e' target=_blank style='color:#2F92EE;'>#IL-4/IL-13单抗Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9673, encryptionId=c5d796e31e, topicName=IL-4/IL-13单抗Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83677370380, createdName=ms5822920152752585, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508289, encodeId=14d61508289b5, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515419, encodeId=ffa515154196e, content=<a href='/topic/show?id=b5e022149cc' target=_blank style='color:#2F92EE;'>#中度至重度特应性皮炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22149, encryptionId=b5e022149cc, topicName=中度至重度特应性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ad510789639, createdName=ms6980045490879608, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802921, encodeId=fac780292189, content=<a href='/topic/show?id=2ad83e51258' target=_blank style='color:#2F92EE;'>#双特异性抗体#</a>真是大火👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37512, encryptionId=2ad83e51258, topicName=双特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jul 15 22:49:45 CST 2020, time=2020-07-15, status=1, ipAttribution=)]
    2020-07-17 jjjiang0202
  7. [GetPortalCommentsPageByObjectIdResponse(id=2057836, encodeId=525e205e836a2, content=<a href='/topic/show?id=9497963485' target=_blank style='color:#2F92EE;'>#IL-13单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9634, encryptionId=9497963485, topicName=IL-13单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Thu Jan 21 00:07:04 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784843, encodeId=26211e8484313, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6331, encryptionId=00e4633166, topicName=Dupixen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Mon Jun 14 12:07:04 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796926, encodeId=93431e969261b, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Wed Jun 02 22:07:04 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372746, encodeId=277713e274656, content=<a href='/topic/show?id=91a7633258' target=_blank style='color:#2F92EE;'>#Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6332, encryptionId=91a7633258, topicName=Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477307, encodeId=d41314e730734, content=<a href='/topic/show?id=c5d796e31e' target=_blank style='color:#2F92EE;'>#IL-4/IL-13单抗Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9673, encryptionId=c5d796e31e, topicName=IL-4/IL-13单抗Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83677370380, createdName=ms5822920152752585, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508289, encodeId=14d61508289b5, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515419, encodeId=ffa515154196e, content=<a href='/topic/show?id=b5e022149cc' target=_blank style='color:#2F92EE;'>#中度至重度特应性皮炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22149, encryptionId=b5e022149cc, topicName=中度至重度特应性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ad510789639, createdName=ms6980045490879608, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802921, encodeId=fac780292189, content=<a href='/topic/show?id=2ad83e51258' target=_blank style='color:#2F92EE;'>#双特异性抗体#</a>真是大火👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37512, encryptionId=2ad83e51258, topicName=双特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jul 15 22:49:45 CST 2020, time=2020-07-15, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2057836, encodeId=525e205e836a2, content=<a href='/topic/show?id=9497963485' target=_blank style='color:#2F92EE;'>#IL-13单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9634, encryptionId=9497963485, topicName=IL-13单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Thu Jan 21 00:07:04 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784843, encodeId=26211e8484313, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6331, encryptionId=00e4633166, topicName=Dupixen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Mon Jun 14 12:07:04 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796926, encodeId=93431e969261b, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Wed Jun 02 22:07:04 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372746, encodeId=277713e274656, content=<a href='/topic/show?id=91a7633258' target=_blank style='color:#2F92EE;'>#Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6332, encryptionId=91a7633258, topicName=Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477307, encodeId=d41314e730734, content=<a href='/topic/show?id=c5d796e31e' target=_blank style='color:#2F92EE;'>#IL-4/IL-13单抗Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9673, encryptionId=c5d796e31e, topicName=IL-4/IL-13单抗Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83677370380, createdName=ms5822920152752585, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508289, encodeId=14d61508289b5, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515419, encodeId=ffa515154196e, content=<a href='/topic/show?id=b5e022149cc' target=_blank style='color:#2F92EE;'>#中度至重度特应性皮炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22149, encryptionId=b5e022149cc, topicName=中度至重度特应性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ad510789639, createdName=ms6980045490879608, createdTime=Fri Jul 17 09:07:04 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802921, encodeId=fac780292189, content=<a href='/topic/show?id=2ad83e51258' target=_blank style='color:#2F92EE;'>#双特异性抗体#</a>真是大火👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37512, encryptionId=2ad83e51258, topicName=双特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jul 15 22:49:45 CST 2020, time=2020-07-15, status=1, ipAttribution=)]
    2020-07-15 lovetcm

    #双特异性抗体#真是大火👍👍

    0

相关资讯

礼来和Incyte宣布其口服JAK抑制剂Baricitinib在中度至重度特应性皮炎患者中进行的3期临床研究BREEZE-AD5的阳性结果

礼来和Incyte宣布,其口服选择性JAK抑制剂baricitinib达到了BREEZE-AD5的主要研究终点。该研究为3期临床、随机安慰剂对照,用于评估Baricitinib治疗成人中重度特应性皮炎(AD)患者安全性和有效性的研究。主要终点指标定义为第16周时,湿疹面积和严重程度指数(EASI)与基线相比至少达到75%或更高比例。

礼来宣布以11亿美元收购Dermira,同时获得中度至重度特应性皮炎III期IL-13单抗lebrikizumab

礼来制药公司已宣布计划以每股18.75美元的现金,总价约11亿美元的价格收购Dermira,以扩大其免疫学管线。作为协议的一部分,礼来公司将获得目前处于三期临床的中度至重度特应性皮炎候选药物lebrikizumab。

Baidu
map
Baidu
map
Baidu
map